Inovio Pharma Says Its Synthetic Vaccine Against Zika Induced Durable Response

(RTTNews) - Inovio Pharmaceuticals, Inc. (INO) Tuesday said the preclinical testing of its synthetic vaccine using SynCon technology for the Zika virus induced durable immune responses.

Inovio is developing the vaccine with GeneOne Life Sciences and academic collaborators. Joseph Kim, Inovio's President and CEO, said, "we rapidly generated a synthetic vaccine candidate that shows promise as a preventive and treatment. With robust antibody and killer T cell responses generated by our vaccine in mice, we will next test the vaccine in non-human primates and initiate clinical product manufacturing. We plan to initiate phase I human testing of our Zika vaccine before the end of 2016."